BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/20/2021 12:47:16 PM | Browse: 422 | Download: 911
 |
Received |
|
2020-07-15 11:59 |
|
Peer-Review Started |
|
2020-07-14 06:43 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-09-29 18:52 |
|
Revised |
|
2020-10-17 04:27 |
|
Second Decision |
|
2020-11-04 10:10 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-11-09 01:20 |
|
Articles in Press |
|
2020-11-09 01:20 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2020-11-15 20:40 |
|
Typeset the Manuscript |
|
2021-01-12 06:17 |
|
Publish the Manuscript Online |
|
2021-01-20 12:47 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu-Qiong Xu, Xiang Long, Ming Han, Ming-Qiang Huang, Jia-Fa Lu, Xue-Dong Sun and Wei Han |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The Sanming Project of Medicine in Shenzhen |
SZSM201911007 |
|
| Corresponding Author |
Wei Han, MD, Associate Chief Physician, Department of Emergency Medicine, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, No.1098 Xueyuan Avenue, Shenzhen 518000, Guangdong Province, China. weihan_dem@163.com |
| Key Words |
Non-small cell lung cancer; COX-2; Survival; Progression-free survival; Systematic review; Randomized controlled trials |
| Core Tip |
This study demonstrated that, in terms of overall response rate (ORR) for patients received adjuvant chemotherapy of advanced non-small cell lung cancer, COX-2 inhibitors improved the ORR and have no improvement on prolonged mortality. However, particularly with first-line chemotherapy, the COX-2 could enhance both the ORR and improved the 1-year survival rate. Concerning toxicity, celecoxib plus chemotherapy resulted in a higher incidence of hematologic toxicities. Meanwhile, the rofecoxib may augment the risk of cardiovascular events. |
| Publish Date |
2021-01-20 12:47 |
| Citation |
Xu YQ, Long X, Han M, Huang MQ, Lu JF, Sun XD, Han W. Clinical benefit of COX-2 inhibitors in the adjuvant chemotherapy of advanced non-small cell lung cancer: A systematic review and meta-analysis. World J Clin Cases 2020; 9(3): 581-601 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i3/581.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i3.581 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
